Kisqali may extend survival and the amount of time you live without metastatic breast cancer getting worse, as part of a combination treatment regimen. In pre- and postmenopausal women, Kisqali has lengthened survival by about a year compared to other treatments, with an overall survival benefit of about 5 years.